CompletedPhase 3NCT01420627
EZN-2279 in Patients With ADA-SCID
Studying Severe combined immunodeficiency due to adenosine deaminase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Leadiant Biosciences, Inc.
- Principal Investigator
- Elie Haddad, MD, PhD, M.DUniversité de Montréal
- Intervention
- EZN-2279(biological)
- Enrollment
- 7 enrolled
- Eligibility
- All sexes
- Timeline
- 2014 – 2019
Study locations (6)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of California San Francisco, San Francisco, California, United States
- National Jewish Health, Denver, Colorado, United States
- UBMD, Buffalo, New York, United States
- Albert Einstein College of Medicine, The Bronx, New York, United States
- Penn State College of Medicine The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01420627 on ClinicalTrials.gov